Active, not recruitingNCT04852068Updated Nov 24, 2023

A Clinical Trial of Freeze-dried Human Rabies Vaccine (Vero Cells)

A Phase 3 interventional study of Freeze-dried human rabies vaccine (Vero cells) Zhifeilongkoma - 5-dose program and Freeze-dried human rabies vaccine (Vero cells) Zhifeilongkoma - 4-dose program in Rabies Vaccine Adverse Reaction and Safety and Efficacy, sponsored by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 10 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-24.

Sponsored by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · Phase 3, Interventional, and Prevention

Phase: Phase 3
Study type: Interventional
Enrollment: 2,480
Allocation: Randomized
Ages: 10 Years to 60 Years
Sex: All

Study summary

This clinical trial is carried out in two phases. The first phase adopts an open design, and the second phase adopts a randomized, blinded, and similar vaccine-controlled non-inferiority trial design.

The first stage: According to the order of two age groups of 18-60 years old and 10-17 years old, 40 cases were enrolled in each age group (20 persons for the 5-dose program and 20 for the 4-dose program). Subjects in the 5-dose group received 1 dose of test vaccine on 0, 3, 7, 14, and 28 days each. Subjects in the 4-dose group received 1 dose each on both arms on day 0, and 1 dose on day 7 and day 21 each. All subjects in the first stage were only observed for safety and were followed up to 6 months after the entire course of vaccination.

The second stage: the total number of enrolled 2400 cases, 10-60 years old, the 4-dose program group and the 5-dose program group of the test vaccine, the 4-dose program group and the 5-dose program group of the control vaccine according to the random ratio 1:1:1:1. Among the total number of participants, 1680 cases (420 cases per group) were simultaneously observed for immunogenicity and safety, and the remaining 720 subjects (180 cases per group) only underwent safety observation. 800 subjects (200 cases in each group) received 6-month immune persistence observation after full vaccination, and 400 subjects in the test vaccine group received 12 months immune persistence observation after full vaccination.

In the second stage, 1680 subjects were collected before the immunization, 7 days after the first dose, 14 days after the first dose, and 14 days after the full vaccination to test rabies virus antibodies to evaluate the immunogenicity of the test vaccine. 800 subjects were in the whole process Immune persistent blood sampling was performed 6 months after vaccination, and subjects in the test vaccine group were further subjected to immune persistent blood sampling 12 months after the full course of vaccination to evaluate immune durability. Collect all AEs within 30 minutes after each dose, AEs from 0-7 days, all non-collective AEs from the first dose to 30 days after the full course of vaccination, and all serious AEs from the first dose to 6 months after the full course of vaccination Adverse events.

Conditions studied

Rabies Vaccine Adverse Reaction
Safety and Efficacy

Browse trials for

Rabies 119

Who can participate

Ages eligible: 10 Years to 60 Years
Sexes eligible: All
Accepts healthy volunteers: Yes

Inclusion criteria

Age 10-60 on the day of enrollment, able to provide legal identification
Subjects and/or their guardians voluntarily agree to participate in the study and sign an adult informed consent form or a minor's informed consent form
Subjects and/or their legal guardians have the ability to understand (non-illiterate) research procedures and participate in all planned follow-ups
On the day of enrollment, the axillary body temperature of people aged 14 and under was \<37.5℃, and the axillary body temperature of people over 14 years of age was \<37.3℃
Female subjects of childbearing age were not breast-feeding at the time of enrollment, were not pregnant (the urine pregnancy test was negative before vaccination (on the day)), had no pregnancy plan within 2 months after enrollment, and agreed to take effective measures within 2 months after enrolling in the study Contraceptive measures

Exclusion criteria

Exclusion Criteria:

Have a history of rabies vaccination or use of rabies virus passive immunization preparations
A history of bites by mammals (such as dogs, cats, etc.) within 1 year before the first dose of vaccination (wound skin damage)
Previous vaccination has a history of severe allergies to any vaccine component that requires medical intervention: such as anaphylactic shock, allergic laryngeal edema, allergic purpura, thrombocytopenic purpura, local allergic necrosis, severe urticaria, etc.
Within 3 days before vaccination, acute febrile disease (body temperature under armpit>38.5℃) or in the acute onset of chronic disease, or taking antipyretic, analgesic, and anti-allergic drugs
Have received blood/blood-related products or immunoglobulins within 3 months before the first dose of vaccination; or plan to use such products within 1 month after the last dose of vaccination
Get any vaccine within 14 days before the first dose of vaccination
Any condition (such as splenectomy) caused asplenia or functional asplenia
Has been diagnosed with congenital or acquired immunodeficiency (HIV), or received immunosuppressive therapy within 3 months
Severe congenital malformations or autoimmune (hereditary) diseases, serious chronic diseases (including but not limited to: heart disease, kidney disease, diabetes with comorbidities, allergic constitution, Guillain-Barre syndrome, etc.), evaluated by the investigator that it may affect research evaluation
People with a history or family history of convulsions, epilepsy, encephalopathy, and psychosis (including but not limited to: congenital brain hypoplasia, brain trauma, brain tumor, cerebral hemorrhage, cerebral obstruction, brain nerve tissue damage caused by infection, chemical drug poisoning, etc.)
There are contraindications for intramuscular injection (diagnosed as any coagulation disorder or receiving anticoagulant treatment)
Are participating in other research or unregistered products (drugs, vaccines or devices, etc.) clinical research, or plan to participate in other clinical research before the end of this clinical research
The researcher believes that the subject has any conditions that may interfere with the evaluation of the research purpose

Study design

Phase: Phase 3
Primary purpose: Prevention
Allocation: Randomized
Intervention model: Parallel assignment
Masking: Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment: 2,480 participants (estimated)

Study arms

Experimental
Investigational Vaccine - 5-dose program
Freeze-dried human rabies vaccine (Vero cells), 0.5ml after reconstitution, with a titer of not less than 2.5IU, Anhui Zhifeilongkoma Biopharmaceutical Co., Ltd.
Biological: Freeze-dried human rabies vaccine (Vero cells) Zhifeilongkoma - 5-dose program
Experimental
Investigational Vaccine - 4-dose program
Freeze-dried human rabies vaccine (Vero cells), 0.5ml after reconstitution, with a titer of not less than 2.5IU, Anhui Zhifeilongkoma Biopharmaceutical Co., Ltd.
Biological: Freeze-dried human rabies vaccine (Vero cells) Zhifeilongkoma - 4-dose program
Active comparator
Control vaccine - 5-dose program
Freeze-dried human rabies vaccine (Vero cells), 0.5ml after reconstitution, titer not less than 2.5IU, Liaoning Chengda Biological Co., Ltd.
Biological: Freeze-dried human rabies vaccine (Vero cells) Chengda - 5-dose program
Active comparator
Control vaccine - 4-dose program
Freeze-dried human rabies vaccine (Vero cells), 0.5ml after reconstitution, titer not less than 2.5IU, Liaoning Chengda Biological Co., Ltd.
Biological: Freeze-dried human rabies vaccine (Vero cells) Chengda - 4-dose program

Interventions

BiologicalFreeze-dried human rabies vaccine (Vero cells) Zhifeilongkoma - 5-dose program
Inoculate 1 dose of Investigational vaccine each on 0, 3, 7, 14, 28 days, by intramuscular injection of deltoid muscle of upper arm
BiologicalFreeze-dried human rabies vaccine (Vero cells) Zhifeilongkoma - 4-dose program
Inoculate 1 dose of Investigational vaccine each on both arms on day 0, and 1 dose each on day 7 and 21, by intramuscular injection of deltoid muscle of upper arm
BiologicalFreeze-dried human rabies vaccine (Vero cells) Chengda - 5-dose program
Inoculate 1 dose of control vaccine each on 0, 3, 7, 14, 28 days, by intramuscular injection of deltoid muscle of upper arm
BiologicalFreeze-dried human rabies vaccine (Vero cells) Chengda - 4-dose program
Inoculate 1 dose of control vaccine each on both arms on day 0, and 1 dose each on day 7 and 21, by intramuscular injection of deltoid muscle of upper arm

What researchers measure

Primary outcomes

Antibody positive conversion rate - Immunogenicity endpoint
Antibody positive conversion rate of the test group and the control group of the pre-immune antibody-negative population
Time frame: 14 days after the first dose of vaccination
Geometric mean concentration - Immunogenicity endpoint
Geometric mean concentration of the test group and the control group of the pre-immune antibody-negative population
Time frame: 14 days after the first dose of vaccination
Incidence of Adverse Events [Safety and Tolerability]
Incidence of Adverse Events
Time frame: within 30 minutes after each dose of vaccination; the first dose of vaccination to 30 days after the full course of vaccination
Incidence of Serious Adverse Events [Safety and Tolerability]
Incidence of Serious Adverse Events
Time frame: The first dose of vaccination to 6 months after the full course of vaccination

Secondary outcomes

Antibody positive conversion rate - Immunogenicity endpoint
Antibody positive conversion rate
Time frame: 7 days after the first dose of vaccination; 14 days, 6 months, 12 months after the full vaccination
Geometric mean concentration - Immunogenicity endpoint
Geometric mean concentration
Time frame: 7 days after the first dose of vaccination; 14 days, 6 months, 12 months after the full vaccination

Study locations

1 site

Hunan Provincial Center for Disease Control and Prevention
Changsha, Hunan 410005, China

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

Registry details

Key details

Study ID: NCT04852068
Lead sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Responsible party: Sponsor
First posted: Apr 21, 2021
Start date: Apr 10, 2021
Primary completion: Sep 30, 2024 (estimated)
Completion: Oct 30, 2024 (estimated)
Last update: Nov 24, 2023

Oversight

Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Rabies→

Other studies from this sponsor

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Start the discussion